Aura Biosciences, Inc. (AURA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US05153U1079
Aura Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -112.79 m USD |
| EBIT | -106.08 m USD |
| Net income | -106.19 m USD |
| Diluted EPS – continuing operations | -1.76 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
More stocks
- Guangzhou Boji Medical and Biotechnological Co Ltd (300404.SZ)
- Zhejiang Hongchang Electrical Technology Co. Ltd. (301008.SZ)
- Huarui Electrical Appliance Co Ltd (300626.SZ)
- Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211.SZ)
- CSBC Corp Taiwan (2208.TW)
- Sabre Corp (SABR)
- Hyundai Energy Solutions Co Ltd (322000.KS)
- Suzhou Huazhijie Telecom Co (603400.SS)
- Shenzhen Weiguang Biological Products Co Ltd (002880.SZ)
- FREQUENCY ELECTRONICS INC (FEIM)
- Ncs Testing Technology Co Ltd (300797.SZ)
- Seche Environnement SA (SCHP.PA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.